Document is current
Any future updates will be listed below
-
Authors
Lambrechts, Roald A
Schepers, Hein
Yu, Yi
van der Zwaag, Marianne
Autio, Kaija J
Vieira‐Lara, Marcel A
Bakker, Barbara M
Tijssen, Marina A
Hayflick, Susan J https://orcid.org/0000-0003-2595-3943
Grzeschik, Nicola A
Sibon, Ody CM https://orcid.org/0000-0002-6836-6063
-
Funding
Funding for this research was provided by:
NIH/NIGMS (R01‐GM084947)
Bloomington Stock Center
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (865.10.012)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (175‐010‐2009‐023)
Academy of Finland (267388)
Sigrid Juselius Foundation
- License Information
-
More Information
Article History
Received: 19 February 2019
Revised: 11 October 2019
Accepted: 15 October 2019
First Online: 7 November 2019
Conflict of interest
: Dr. Hayflick and Dr. Sibon are co‐inventors on a patent application for 4′‐phosphopantetheine for use in disorders exclusive of PKAN. Dr. Sibon is a co‐inventor on a patent application for acetyl‐4′‐phosphopantetheine for use in PKAN and in related disorders. Dr. Hayflick is a non‐compensated member of the Scientific Advisory Board of BioPontis Alliance, a non‐profit organization. Dr. Hayflick is a non‐compensated member of the Scientific and Medical Advisory Board of the NBIA Disorders Association, a non‐profit lay advocacy organization. Dr. Hayflick is a non‐compensated member of the Scientific and Medical Advisory Board of the NBIA Alliance, a non‐profit lay advocacy organization. Dr. Hayflick serves as non‐compensated executive for the Spoonbill Foundation, a not‐for‐profit organization that may benefit from the results of this research and technology. Dr. Sibon serves as non‐compensated executive for the Stichting Lepelaar, a not‐for‐profit organization that may benefit from the results of this research and technology. This potential conflict of interest has been reviewed and managed by OHSU and the UMCG.
